# Eli Lilly Q3 2026: The GLP-1 Price Cut Its Margin Absorbed — InvestMoat Research _Lilly's realized GLP-1 prices fell 15% in Q3 2026, and the worry is that the price war has started eating its moat. If unit costs had stayed flat, that cut would have pulled its gross margin down to about 81%. It printed 84.4%. I read that gap as manufacturing scale being spent, and it's the number to watch._ _Published: October 31, 2026 · Last reviewed: October 31, 2026 · Canonical page: https://www.investmoat.com/research/lilly-q3-and-the-price-cut-the-margin-absorbed_ _Tags: Healthcare, GLP-1, Earnings_ _Covers: LLY, NVO, HIMS, REGN, VRTX_ ## Summary Eli Lilly reported Q3 2026 on October 29: revenue up 39% to $24.4 billion, on 53% more volume and 15% lower realized prices. Over the last five quarters the year-on-year price decline ran from 5% to 15%, and in every quarter Lilly's non-GAAP gross margin came in above what the year-ago margin would have become after that price cut with unit costs unchanged, by under a point when the cut was 5% and by about 1.5 to 3.7 points when it was 10% or more. I read that gap as Lilly's manufacturing scale paying for the price cuts, which makes its GLP-1 moat a cost advantage rather than pricing power. The strongest objection is that milestones and rebate adjustments flatter the margin in every 2026 quarter; stripping out Q3's roughly $900 million of one-offs still leaves a gap of about three points, and the claim below is set on that gap. ## What would prove this wrong If, in any quarter of 2027, Lilly's non-GAAP gross margin is no higher than its year-ago margin would be after that quarter's reported realized-price decline with unit costs unchanged (the calculation in this article's chart), the price cuts are coming out of margin rather than out of unit cost, and my read that they are Lilly's scale advantage at work is wrong. _Status as of October 31, 2026: **holding**._ --- Q3 2026 realized price: −15% · Q3 2026 volume: +53% · Non-GAAP gross margin: 84.4% · Lilly price: (live) Lilly collected 15% less per dose in Q3 2026 than a year earlier, its steepest price drop in five quarters. The worry I keep seeing is that this is the GLP-1 price war arriving, with government deals, Novo Nordisk's price resets, pills and compounded copies pushing the drugs toward commodity pricing. I think the margin says something else. If Lilly's costs per dose had stayed where they were, a 15% price cut would have taken its gross margin to about 81%. It reported 84.4%. That gap is the whole argument. If Lilly's edge were pricing power, every point of price it gave up would come straight out of margin. If its edge is that it makes these drugs at lower cost than anyone else, and keeps getting cheaper as volume grows, the margin holds while price falls. The second is what the last five quarters look like to me. ## Price fell, volume kept running ahead **Lilly's year-on-year price decline tripled in three quarters, from 5% in Q4 2025 to 15% in Q3 2026, while volume growth stayed above 45%. Worldwide change as reported in each quarter's release. Q3 2025's price figure includes a US base-period effect the release calls out.** | Period | Volume | Realized price | | --- | --- | --- | | Q3 2025 | 62% | -10% | | Q4 2025 | 46% | -5% | | Q1 2026 | 65% | -13% | | Q2 2026 | 60% | -13% | | Q3 2026 | 53% | -15% | _Figures as of Q3 2026, Lilly earnings releases, October 30, 2025 to October 29, 2026. Source: [Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2025-financial-results-highlights-rd); [Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-fourth-quarter-2025-financial-results-and-provides); [Lilly reports first-quarter 2026 financial results, raises full year guidance](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-first-quarter-2026-financial-results-raises-full); [Lilly reports second-quarter 2026 financial results, raises full-year guidance](https://investor.lilly.com/node/54781); [Lilly reports third-quarter 2026 financial results, raises full-year guidance](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full)._ The bears are right that the price line is getting worse. Volume growth has still beaten the price decline by roughly 40 to 50 points every quarter, so revenue kept compounding, and the split inside Q3 shows where the cut went. **Where the Q3 2026 price cut fell. Outside the US, Lilly gave up nearly a third of its price and sold three quarters more.** | Region | Revenue | Growth | Volume | Realized price | | --- | --- | --- | --- | --- | | United States | $15.1B | +34% | +41% | −7% | | Outside the US | $9.3B | +47% | +76% | −29% | | Worldwide | $24.4B | +39% | +53% | −15% | _Figures as of Q3 2026, Lilly earnings release, October 29, 2026. Source: [Lilly reports third-quarter 2026 financial results, raises full-year guidance](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full)._ Most of the worldwide decline is outside the US, where Mounjaro grew 93% to $5.7 billion. The release doesn't say which markets or price tiers drove it, so I won't guess. What matters for the moat is what the cut did to the margin. ## What the margin would have been with flat costs Here's the check I ran. Take the gross margin from the same quarter a year earlier, cut the price by that quarter's reported decline, and keep the cost per dose the same. That's the margin Lilly would have printed with no cost improvement at all. The gap between that and the margin it actually reported is what lower unit costs (and anything else, such as product mix) paid for. The margin here is non-GAAP, which for Lilly's gross margin only strips out amortization of acquired intangibles, so one-offs like milestone payments are still in it. **Lilly's reported non-GAAP gross margin against my estimate of the margin with unit costs unchanged: the year-ago margin after that quarter's reported price decline. The gap is positive in every quarter and widest in Q3 2026, the biggest cut. Q3 2026's reported figure includes about $900 million of one-off benefits; without them I get roughly 83.8%.** | Period | Reported | With unit costs unchanged | | --- | --- | --- | | Q3 2025 | 83.6% | 80.2% | | Q4 2025 | 83.2% | 82.3% | | Q1 2026 | 82.6% | 81% | | Q2 2026 | 86.3% | 82.8% | | Q3 2026 | 84.4% | 80.7% | _Figures as of Q3 2026, Lilly earnings releases, October 30, 2025 to October 29, 2026; flat-cost line is my calculation. Source: [Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2025-financial-results-highlights-rd); [Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-fourth-quarter-2025-financial-results-and-provides); [Lilly reports first-quarter 2026 financial results, raises full year guidance](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-first-quarter-2026-financial-results-raises-full); [Lilly reports second-quarter 2026 financial results, raises full-year guidance](https://investor.lilly.com/node/54781); [Lilly reports third-quarter 2026 financial results, raises full-year guidance](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full)._ When the cut was small, as in Q4 2025 at 5%, the gap was under a point. When it was 10% or more, the gap ran from 1.6 points in Q1 2026 to more than three points in the other three quarters, and it was widest in Q3 2026, the biggest cut. It doesn't rise neatly with the size of the cut, but a margin that beats the flat-cost line in every quarter looks to me like a cost curve being passed on, which is what a scale advantage should look like. > **INSIGHT** — When a drug's price falls, work out what the gross margin would have been with costs unchanged before you call it moat erosion. A margin that beats that line is being supported by lower cost per unit. A margin that lands on it or below is pricing power giving way. ## Why the cost per dose keeps falling GLP-1 drugs are peptides, which are hard to make in bulk, and the lines that fill injectable pens take years to build. Lilly says it has announced 10 new US sites since 2020, with new expansions in Texas and Virginia in the Q3 release. Plants like these have high fixed costs and low costs for each extra dose, so the more doses run through them, the cheaper each one gets. Lilly doesn't report cost per dose, so this is my reading of the margin, but it fits: cut price, sell more, spread the fixed cost wider. Lilly also raised its 2026 revenue guide to $91 to $92 billion from $85 to $87 billion in the same quarter its price fell fastest. A company whose moat was eroding under price pressure wouldn't usually be raising its sales outlook this hard. ## The margin was flattered, and the cuts aren't Lilly's choice The strongest case against me starts with the one-offs. Lilly says Q3 revenue included about $900 million of benefits, including $410 million of milestone payments on Jardiance, a diabetes drug it sells with Boehringer Ingelheim, plus favorable adjustments to rebates and discounts. The release says all three quarters of 2026 had milestones of this kind, and Q2 had rebate adjustments big enough that US price would have fallen about 9% rather than 3% without them. Revenue like that has almost no cost, so it lifts the gross margin. I tried to size it. Take the $900 million out of Q3 revenue and assume none of it had any cost, and the margin falls from 84.4% to about 83.8%. That's still about three points above the flat-cost line. Lilly says no further Jardiance milestones remain, so Q4 2026 will be the first clean read. The second objection is that Lilly isn't choosing these cuts. Lilly says the US decline came mainly from Zepbound, and the release's own risk language points to its voluntary pricing agreement with the US government. On this view the cuts are imposed and permanent, and mix and milestones, not scale, have held the margin so far. I think that's partly right about the cause, and it doesn't change the test. Whether a price cut is chosen or forced, the question is who can afford it, and so far the margin says Lilly can. The third is direction. The price decline tripled in three quarters, and volume growth slowed from 65% in Q1 to 53% in Q3, with Mounjaro's growth falling from 125% to 65%. If the two lines keep converging, there's a point where volume no longer outruns price and revenue growth stalls however cheaply Lilly makes the drug. And if the category moves to pills, which need far less pen-filling capacity, the plants Lilly built are worth less. Novo already sells a Wegovy pill, and Lilly's own, Foundayo, sold $184 million in its first full quarter. I'd count a quarter where price falls faster than volume grows as a real strike against me. ## Only Novo can run the same play Price pressure doesn't land the same way across drug names, and the framework's moat ratings show why. Regeneron and Vertex are in the table as the contrast: their moats rest on patents and drugs nobody else sells, so they have no volume loop to fall back on if price drops. Hims & Hers sells Novo's branded GLP-1s on a subscription platform, so a cheaper Lilly drug is a rival offer it has to compete with. **Live scores for the five covered drug and drug-access names this piece reads. Novo Nordisk and Hims & Hers had not reported Q3 2026 as of October 31, 2026.** | Ticker | Name | Moat | Growth | Valuation | Composite | Note | | --- | --- | --- | --- | --- | --- | --- | | **GLP-1 makers** | | | | | | | | [LLY](https://www.investmoat.com/stocks/lly) | Eli Lilly and Company | 71 | 81 | 66 | 73 | Price −15%, volume +53% in Q3 2026 | | [NVO](https://www.investmoat.com/stocks/nvo) | Novo Nordisk | 54 | 49 | 85 | 59 | The other GLP-1 maker at scale; reports Q3 in early November | | **GLP-1 distribution** | | | | | | | | [HIMS](https://www.investmoat.com/stocks/hims) | Hims & Hers Health | 54 | 73 | 76 | 67 | Sells Novo's branded GLP-1s by subscription | | **Patent-led pharma** | | | | | | | | [REGN](https://www.investmoat.com/stocks/regn) | Regeneron Pharmaceuticals, Inc. | 76 | 68 | 71 | 72 | Antibody franchises protected by patents | | [VRTX](https://www.investmoat.com/stocks/vrtx) | Vertex Pharmaceuticals Incorporated | 70 | 74 | 66 | 70 | Cystic fibrosis drugs with no direct rival | _Valuation and composite above use each asset's static valuation score; the live site recomputes them against the current market price._ **The pillars that decide who can keep cutting GLP-1 prices. Statuses are read live from each stock's analysis.** | Ticker | Scale Economics | Regulatory Lock-In | Transaction Embedding | | --- | --- | --- | --- | | [LLY](https://www.investmoat.com/stocks/lly) | strong | intact | intact | | [NVO](https://www.investmoat.com/stocks/nvo) | intact | intact | weakened | | [HIMS](https://www.investmoat.com/stocks/hims) | na | na | intact | | [REGN](https://www.investmoat.com/stocks/regn) | na | strong | intact | | [VRTX](https://www.investmoat.com/stocks/vrtx) | na | strong | intact | Lilly's scale economics are rated strong and Novo Nordisk's intact; the pillar doesn't apply at the other three. Novo is the only other company making these drugs at this volume, so it's the real test of whether scale decides who wins the price war. If its Q3 shows price falling without the margin holding, that's the price war the bears describe, landing on the company with less scale. ## Two dates and one line > **RISK** — What would break this: (1) any 2027 quarter where Lilly's non-GAAP gross margin is no higher than the flat-cost line in the chart above, which trips the claim; (2) a quarter where the price decline is larger than volume growth, so revenue falls on price; (3) Novo Nordisk holding its margin through similar cuts at lower volume, which would mean scale isn't what's paying for them. The first checks are Novo's Q3 report in early November and Lilly's Q4 2026 report, its first quarter without Jardiance milestones. ## Sources 1. [Lilly reports third-quarter 2026 financial results, raises full-year guidance](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full) — Eli Lilly and Company, October 29, 2026 (press-release) 2. [Lilly reports second-quarter 2026 financial results, raises full-year guidance](https://investor.lilly.com/node/54781) — Eli Lilly and Company, August 5, 2026 (press-release) 3. [Lilly reports first-quarter 2026 financial results, raises full year guidance](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-first-quarter-2026-financial-results-raises-full) — Eli Lilly and Company, April 30, 2026 (press-release) 4. [Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-fourth-quarter-2025-financial-results-and-provides) — Eli Lilly and Company, February 4, 2026 (press-release) 5. [Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2025-financial-results-highlights-rd) — Eli Lilly and Company, October 30, 2025 (press-release) --- Scores are computed deterministically from each asset's data file: composite = Moat^0.40 × Growth^0.30 × Valuation^0.30, scaled to 0–100. Full analyses for every name above: https://www.investmoat.com/stocks. Site index for agents: https://www.investmoat.com/llms.txt InvestMoat is an open-source research and education framework. Nothing here is financial advice.